EUVIMEDOdkrijte EUVIMED
Open access

COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies

Kai Chen, Kentaro Takeda iD, Ying Yuan iD

Statistics in Medicine · 2025

DOI: 10.1002/sim.70107 ↗

At a glance

Journal article in Statistics in Medicine, 2025. Written by Kai Chen and 2 co-authors. Institution: Department of Biostatistics and Data Science, The University of Texas Health Science Center, Houston, Texas, USA. Major MEDLINE topics: Immunotherapy, Adoptive. Cited 2 times so far (Crossref); 26 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, National Cancer Institute.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Project Optimus, initiated by the US Food and Drug Administration (FDA), seeks to shift the focus of dose finding and selection from the maximum tolerated dose to the optimal dose that offers the most favorable risk‐benefit balance. However, applying this paradigm shift to drug combination trials presents challenges, particularly due to limited sample sizes and a large two‐dimensional dose exploration space. These challenges are amplified when trials involve multiple indications. To address this, we developed a two‐stage Bayesian dose optimization design, called COMIC (Combination Optimization in Multiple IndiCations), to efficiently identify Optimal Biological Dose Combinations (OBDC) for multiple indications. The COMIC design follows a two‐stage strategy: First, optimizing the dose for one indication based on a utility function that measures the risk‐benefit tradeoff, and then using that data to inform and accelerate dose optimization for additional indications. This approach significantly reduces the required sample size. Additionally, we incorporate a pharmacodynamic endpoint (e.g., receptor occupancy) to prioritize which component of the combination should be escalated, further enhancing the efficiency of dose optimization. Simulation studies demonstrate the strong performance and robustness of the COMIC design across various scenarios. We illustrate the method using a CAR‐T therapy trial.

Subjects

MeSH terms (MEDLINE)

Immunotherapy, AdoptiveBayes TheoremHumansComputer SimulationDose-Response Relationship, DrugMaximum Tolerated DoseUnited StatesDrug Therapy, CombinationUnited States Food and Drug AdministrationModels, StatisticalSample SizeClinical Trials as Topic

Author keywords

dose optimizationdrug combinationmultiple indicationsoptimal biological dose combinationsproject optimus

Authors and institutions

  • Department of Biostatistics and Data Science, The University of Texas Health Science Center, Houston, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Astellas Pharma Global Development Inc., Northbrook, Illinois, USA.

ORCID profiles: Kentaro Takeda, Ying Yuan

Funding

  • NCI NIH HHS
  • National Cancer Institute

Cite

APA

Chen, K., Takeda, K., & Yuan, Y. (2025). COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies. Statistics in Medicine. https://doi.org/10.1002/sim.70107

Vancouver

Chen K, Takeda K, Yuan Y. COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies. Statistics in Medicine. 2025. doi:10.1002/sim.70107

BibTeX
@article{Chen2025,
  author = {Chen, Kai and Takeda, Kentaro and Yuan, Ying},
  title = {COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70107}
}
Start for free →